CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
Randomized Phase III second-line trial: Topotecan (TM) vs. Topotecan/Etoposide (TE), vs. Topotecan/Gemcitabine (TG) for patients (pts) with relapsed ovarian cancer (ROC)
DOI 10.1055/s-2006-952260
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Sehouli, H Sommer, P Klare, HJ Hindenburg, O Camara, W Lichtenegger
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe09/2006
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Topotecan combined with etoposide (GINECO 1998) and gemcitabine (NOGGO 2001) proved effective second-line treatment for ROC. It is, however, unclear whether combined treatment improves survival and tumor control compared to TM. Methods: Women with ROC after primary surgery and platinum therapy were enrolled in an open-label randomized phase-III trial at 93 German institutions. Stratifying for treatment-free in…
Zitieren
Zitierempfehlung
J Sehouli, H Sommer, P Klare, HJ Hindenburg, O Camara, W Lichtenegger (2006) Randomized Phase III second-line trial: Topotecan (TM) vs. Topotecan/Etoposide (TE), vs. Topotecan/Gemcitabine (TG) for patients (pts) with relapsed ovarian cancer (ROC). Geburtshilfe und Frauenheilkunde (09). https://doi.org/10.1055/s-2006-952260
Mit CareLit weiterarbeiten